Fintel reports that on June 21, 2024, Rodman & Renshaw initiated coverage of Alto Neuroscience (NYSE:ANRO) with a Buy recommendation.
Analyst Price Forecast Suggests 198.46% Upside
As of June 12, 2024, the average one-year price target for Alto Neuroscience is 32.98. The forecasts range from a low of 32.32 to a high of $34.65. The average price target represents an increase of 198.46% from its latest reported closing price of 11.05.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Alto Neuroscience is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -1.73.
What is the Fund Sentiment?
There are 80 funds or institutions reporting positions in Alto Neuroscience. This is an increase of 78 owner(s) or 3,900.00% in the last quarter.
What are Other Shareholders Doing?
Falcon Edge Capital holds 3,708K shares representing 13.80% ownership of the company.
Ra Capital Management holds 1,385K shares representing 5.16% ownership of the company.
Point72 Asset Management holds 1,125K shares representing 4.19% ownership of the company.
72 Investment Holdings holds 668K shares representing 2.48% ownership of the company.
Price T Rowe Associates holds 638K shares representing 2.37% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
